ABCL — AbCellera Biologics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual cashflow statement for AbCellera Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	153	159	-146	-163	-146
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items	37	63.3	62.9	-10.7	63.6
Unusual Items
Other Non-Cash Items
Changes in Working Capital	41.7	29.8	13.2	-25.8	-70.7
Change in Accounts Receivable
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities	245	277	-43.9	-109	-131
Capital Expenditures	-58.5	-72.7	-77.5	-78.4	-42.8
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-274	-280	-144	200	131
Acquisition of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-332	-353	-221	121	87.8
Financing Cash Flow Items	-7.55	-4.06	-1.23	-0.729	-15.6
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-3.89	-1.63	10.4	12.8	14.1
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-93	-86.5	-254	23	-28.4